INTRODUCTION {#s1}
============

Cancer is the result of complex interactions between inherited and environmental factors, which threatens people worldwide due to high morbidity and mortality \[[@R1]\]. Although the aetiology of this disease remains unclear, genetic susceptibility is one known explanation for the inter-individual variation in cancer risk \[[@R2]\]. Many researchers have been studying the aetiology of oncogenesis, and have identified the relationship between genetic polymorphism and cancer risk, especially for the *NFKB1* −94ins/del ATTG promoter polymorphism.

*NFKB* is responsible for regulating the expression of many genes for immune response, cell adhesion, differentiation, proliferation, angiogenesis and apoptosis \[[@R3]\]. *NFKB* was first identified by Sen and Baltimore in 1986 \[[@R4]\]. As a transcription factor, *NFKB* binds to a 10 bp DNA element in kappa immunoglobulin light-chain enhancer in B cells \[[@R5]\]. The *NFKB* family consists of p50/p105, p65/Rel A, c-Rel, Rel B, and p52/p100. Among them, the major form of *NFKB* is a heterodimer of the p50/p105 and p65/Rel A subunits that are encoded by the *NFKB1* and *NFKB2* genes, respectively \[[@R49]\]. The human *NFKB1* gene, located on chromosome 4q24, encodes a 50 kDa DNA-binding protein that can act as a master regulator of inflammation and cancer development \[[@R6],[@R7]\].

A common insertion/deletion polymorphism in the promoter region of the *NFKB1* gene elicits a regulatory effect on the *NFKB1* gene \[[@R8]\] and an increasing number of studies have assessed the association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer risk \[[@R9]--[@R11]\]. However, some researchers could not replicate this association. Previous meta-analysis \[[@R45]--[@R48]\] focused on the relationship between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer, but the results were inconsistent. Since then, several other studies \[[@R36]--[@R44]\] performed on large case and control groups have assessed the relationships between the *NFKB1* −94ins/del ATTG promoter polymorphism and susceptibility to a variety of cancers. Therefore, to better understand the precise relationships, we performed a comprehensive updated meta-analysis with increased statistical power.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

Our electronic database search resulted in 202 articles and 2 articles were available manually, we scanned all of the abstracts, and there were 45 articles that conformed to the inclusion criteria, we excluded 9 articles \[[@R52]--[@R60]\] that did not conform to HWE, 2 studies \[[@R61], [@R62]\] were excluded as they were duplications of previous publications and 1 study \[[@R63]\] did not have completely extractable data. Thus, we included 33 independent records \[[@R14]--[@R44], [@R50]--[@R51]\]. Riemann et al \[[@R15]\] was treated as three independent case groups because three cancer types were studied along with a control sample. Li et al \[[@R39]\] conducted their research in three types of urinary cancer (renal cancer, bladder cancer and prostate cancer), so we treated the data as three separate comparisons. Finally, a total of 37 separate studies involving 16,271 cases and 22,781 controls were available for our updated meta-analysis. Figure [1](#F1){ref-type="fig"} describes the process for the study. Characteristics of the eligible studies are summarized in Table [1](#T1){ref-type="table"}. Among them, 26 studies were performed in Asian populations and 11 studies in Caucasian populations. In total, this meta-analysis included 5 studies on colorectal cancer studies, 4 on bladder cancer studies, 4 on ovarian cancer studies, 4 on prostate cancer studies, 3 on hepatocellular carcinoma studies, 3 on nasopharyngeal carcinoma studies, 2 on gastric cancer studies, 2 on oral squamous cell carcinoma studies, 2 on non-small cell lung cancer studies, 2 on renal cell cancer studies and 5 on other cancers. All cases were clinically pathologically confirmed.

###### Characteristics of studies included in the meta-analysis

  Author      Year   Ethnicity   Country   Cases   Control   Method     Cancer type    Case   Control   HWE                     
  ----------- ------ ----------- --------- ------- --------- ---------- -------------- ------ --------- ----- ----- ----- ----- -------
                                                                                       II     ID        DD    II    ID    DD    
  Lin         2006   Asian       China     212     201       PCR        OSCC           59     103       50    43    100   58    0.993
  Riemann     2006   Caucasian   Germany   139     307       PCR-RFLP   CRC            54     58        27    118   141   48    0.586
  Riemann     2006   Caucasian   Germany   72      307       PCR-RFLP   B cell CLL     18     41        13    118   141   48    0.586
  Riemann     2006   Caucasian   Germany   140     307       PCR-RFLP   RCC            47     76        17    118   141   48    0.586
  Riemann     2007   Caucasian   Germany   242     307       PCR-RFLP   BC             88     124       30    118   141   48    0.586
  Lo          2009   Asian       China     182     116       PCR        GC             62     89        31    20    62    34    0.361
  He          2009   Asian       China     202     404       PCR-RFLP   HCC            83     84        35    97    183   124   0.07
  Zhang       2009   Asian       China     117     143       PCR-PAGE   PC             46     57        14    44    68    31    0.624
  Zhou        2009   Asian       China     163     203       PCR-RFLP   NPC            74     67        22    71    90    42    0.177
  Zhou        2010   Asian       China     233     365       PCR-PAGE   CSCC           108    105       20    135   166   64    0.297
  Andersen    2010   Caucasian   Denmark   378     756       TaqMan     CRC            121    195       62    307   347   102   0.801
  Tang        2010   Asian       China     207     228       PCR-PAGE   BC             89     92        26    74    108   46    0.565
  Song        2011   Asian       China     1001    1005      PCR-RFLP   CRC            363    500       138   297   522   186   0.102
  Fan         2011   Asian       China     179     223       PCR-CE     OC             78     84        17    76    103   44    0.396
  Vangsted    2012   Caucasian   Denmark   348     1700      Taqman     MM             110    163       55    665   778   253   0.303
  Ungerback   2012   Caucasian   Sweden    344     622       TaqMan     CRC            114    187       43    256   270   96    0.079
  Liu         2012   Asian       China     906     906       PCR        NPC            269    467       170   280   433   193   0.289
  Lin         2012   Asian       China     462     520       TaqMan     OSCC           116    246       100   81    271   168   0.099
  Kopp        2013   Caucasian   Denmark   334     334       TaqMan     PC             128    152       54    109   161   64    0.741
  Huo         2013   Asian       China     187     221       PCR        OC             83     82        22    71    103   47    0.399
  Cheng       2013   Asian       China     135     520       RT-PCR     HCC            42     64        29    81    271   168   0.099
  Li          2013   Asian       China     609     640       TaqMan     BC             189    269       151   223   324   93    0.156
  Oltulu      2014   Caucasian   Turkey    95      99        PCR-RFLP   NSCLC          35     44        16    46    47    6     0.18
  Hua         2014   Asian       China     401     433       HapMap     GC             92     182       127   120   230   83    0.144
  Zhang       2014   Asian       China     624     1606      PCR        HCC            205    312       107   542   790   274   0.63
  Liu         2015   Asian       China     1590    1979      HapMap     NPC            552    769       269   610   950   419   0.169
  Wang        2015   Asian       China     421     425       PCR-RFLP   NSCLC          113    219       89    89    205   131   0.595
  Lu          2015   Asian       China     687     687       PCR-RFLP   OC             115    351       221   95    339   253   0.271
  Kopp        2015   Caucasian   Denmark   915     1719      KASP       CRC            320    449       146   679   787   253   0.311
  Chen        2015   Asian       China     410     442       PCR        OC             120    195       95    85    235   122   0.136
  Li          2015   Asian       China     730     780       TaqMan     BC             227    316       187   261   395   124   0.208
  Li          2015   Asian       China     1216    1588      TaqMan     RCC            451    577       188   582   781   225   0.152
  Li          2015   Asian       China     820     945       TaqMan     PC             299    377       144   347   462   136   0.371
  Wang        2015   Asian       China     352     459       PCR        PTC            106    186       60    171   209   79    0.273
  Li          2015   Asian       China     220     222       PCR-RFLP   Osteosarcoma   60     114       46    50    106   66    0.55
  Han         2015   Asian       China     936     936       PCR-RFLP   PC             63     339       534   38    331   567   0.23
  Rybka       2016   Caucasian   Poland    62      126       PCR        AML            25     30        7     43    69    14    0.079

PTC papillary thyroid carcinoma, CRC colorectal cancer, BC, bladder cancer, OC ovarian cancer, PC prostate cancer, HCC hepatocellular carcinoma, GC gastric cancer, OSCC oral squamous cell carcinoma, NSCLC none small cell lung cancer, NPC nasopharyngeal carcinoma, RCC renal cell carcinoma, MM multiple myeloma, AML acute myeloid leukaemia

![Flow chart of the process for study identification and selection](oncotarget-07-58659-g001){#F1}

Meta-analysis of the overall population {#s2_2}
---------------------------------------

The main meta-analysis results of the association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer risk are shown in Table [2](#T2){ref-type="table"}. All *P* values displayed obvious heterogeneity between the selected research studies under all five genetic models of the updated meta-analysis. Thus, the random-effect model was used. We found that the *NFKB1* −94ins/del ATTG promoter polymorphism was significantly increased cancer risk in homozygote (II *vs*. DD, OR = 1.259, 95% CI = 1.068-1.485), recessive (II *vs*. ID+DD, OR = 1.140, 95% CI = 1.029-1.263) and allele (I *vs*. D, OR = 1.109, 95% CI = 1.025-1.199) genetic models. However, the association was not found in II+ID *vs*. DD (OR = 1.139, 95% CI = 0.994-1.305) and ID *vs*. DD (OR = 1.118, 95% CI = 0.997-1.253). (Figure [2](#F2){ref-type="fig"}).

![Forest plots of ORs with 95% CI for the *NFKB1* −94ins/del ATTG promoter polymorphism and risk of cancer in the overall population (II *vs*. ID + DD)](oncotarget-07-58659-g002){#F2}

Subgroup analyses {#s2_3}
-----------------

The subgroup analysis for ethnicity revealed significant increases in susceptibility for cancer risk in the four models among Asians (II+ID *vs*. DD, OR = 1.223, 95% CI = 1.031-1.451; II *vs*. ID+DD, OR = 1.280, 95% CI = 1.142-1.435; II *vs*. DD, OR = 1.463, 95% CI = 1.196-1.788; I *vs*. D, OR = 1.199, 95% CI = 1.092-1.317) and decreases in susceptibility in three models among Caucasians (II *vs*. ID+DD, OR = 0.824, 95% CI = 0.752-0.903; II *vs*. DD, OR = 0.855, 95% CI = 0.748-0.979; I *vs*. D, OR = 0.899, 95% CI = 0.844-0.958). (Figure [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The stratified analyses revealed a significant association between the polymorphism and ovarian cancer (II+ID *vs*. DD, OR = 1.481, 95% CI = 1.128-1.943; II *vs*. ID+DD, OR = 1.503, 95% CI = 1.265-1.786; II *vs*. DD, OR = 1.761, 95% CI = 1.420-2.184; ID *vs*. DD, OR = 1.246, 95% CI = 1.048-1.482; I *vs*. D, OR = 1.308, 95% CI = 1.181-1.449), oral squamous cell carcinoma (II+ID *vs*. DD, OR = 1.593, 95% CI = 1.253-2.026; II *vs*. ID+DD, OR = 1.674, 95% CI = 1.292-2.169; II *vs*. DD, OR = 2.104, 95% CI = 1.545-2.867; ID *vs*. DD, OR = 1.420, 95% CI = 1.102-1.829; I *vs*. D, OR = 1.427, 95% CI = 1.229-1.657) and nasopharyngeal carcinoma (II *vs*. DD, OR = 1.339, 95% CI = 1.040-1.724; ID *vs*. DD, OR = 1.257, 95% CI = 1.092-1.447; I *vs*. D, OR = 1.158, 95% CI = 1.002-1.337) in the models. However, we did not find associations in hepatocellular carcinoma, colorectal cancer, bladder cancer, prostate cancer, non-small cell lung cancer and renal cell cancer (Table [2](#T2){ref-type="table"}).

###### Associations between the NFKB1 −94ins/del ATTG promoter polymorphism and cancer risk

                                                                                        II+ID *vs*. DD                                                    II *vs*. ID+DD                                                    II *vs*. DD                                                       ID *vs*. DD                                                       I *vs.* D                                                
  ------------------------------ --------------------------------------- -------------- -------------------------------------------------------- -------- -------------------------------------------------------- -------- -------------------------------------------------------- -------- -------------------------------------------------------- -------- -------------------------------------------------------- --------
  Variables                      N[^a^](#tfn_001){ref-type="table-fn"}   Case/Control   OR (95% CI)                                              I^2^ %   OR (95% CI)                                              I^2^ %   OR (95% CI)                                              I^2^ %   OR (95% CI)                                              I^2^ %   OR (95% CI)                                              I^2^ %
  **Overall**                    37                                      16271/22781    1.139(0.994-1.305)[^b^](#tfn_002){ref-type="table-fn"}   83.2     1.140(1.029-1.263)b                                      78       1.259(1.068-1.485)b                                      84.0     1.118(0.997-1.253)[^b^](#tfn_002){ref-type="table-fn"}   72.6     1.109(1.025-1.199)b                                      84.2
  **Ethnicity**                                                                                                                                                                                                                                                                                                                                                                                                          
  Asian                          26                                      13202/16197    1.223(1.031-1.451)b                                      87.3     1.280(1.142-1.435)b                                      76.3     1.463(1.196-1.788)b                                      86.6     1.151(0.999-1.327)[^b^](#tfn_002){ref-type="table-fn"}   78.8     1.199(1.092-1.317)b                                      86.0
  Caucasian                      11                                      3069/6584      0.957(0.847-1.081)                                       27.5     0.824(0.752-0.903)                                       39.9     0.855(0.748-0.979)                                       36.2     1.045(0.918-1.188)                                       24.8     0.899(0.844-0.958)                                       36.1
  **Cancer types**                                                                                                                                                                                                                                                                                                                                                                                                       
  Colorectal cancer              5                                       2777/4409      1.025(0.796-1.319)[^b^](#tfn_002){ref-type="table-fn"}   68.3     0.890(0.675-1.173)[^b^](#tfn_002){ref-type="table-fn"}   85       0.947(0.660-1.360)[^b^](#tfn_002){ref-type="table-fn"}   81.4     1.103(0.959-1.269)                                       49.9     0.946(0.785-1.140)[^b^](#tfn_002){ref-type="table-fn"}   84.4
  Bladder cancer                 4                                       1788/1955      0.827(0.464-1.475)[^b^](#tfn_002){ref-type="table-fn"}   90.3     0.983(0.782-1.236)[^b^](#tfn_002){ref-type="table-fn"}   60.8     0.893(0.510-1.564)[^b^](#tfn_002){ref-type="table-fn"}   87.1     0.830(0.494-1.394)[^b^](#tfn_002){ref-type="table-fn"}   86.3     0.948(0.733-1.227)[^b^](#tfn_002){ref-type="table-fn"}   85.7
  Ovarian cancer                 4                                       1463/1573      1.481(1.128-1.943)b                                      51.6     1.503(1.265-1.786)                                       0        1.761(1.420-2.184)                                       39.8     1.246(1.048-1.482)                                       37.9     1.308(1.181-1.449)                                       38.5
   Prostate cancer               4                                       2207/2358      1.099(0.753-1.604)[^b^](#tfn_002){ref-type="table-fn"}   82.0     1.266(0.978-1.639)[^b^](#tfn_002){ref-type="table-fn"}   57.6     1.382(0.864-2.210)[^b^](#tfn_002){ref-type="table-fn"}   78.2     1.039(0.797-1.355)[^b^](#tfn_002){ref-type="table-fn"}   59.1     1.138(0.955-1.357)[^b^](#tfn_002){ref-type="table-fn"}   69.5
   Gastric cancer                2                                       583/549        0.997(0.260-3.826)[^b^](#tfn_002){ref-type="table-fn"}   94.3     1.353(0.434-4.221)[^b^](#tfn_002){ref-type="table-fn"}   91.8     1.275(0.195-8.331)[^b^](#tfn_002){ref-type="table-fn"}   95.5     0.879(0.295-2.613)[^b^](#tfn_002){ref-type="table-fn"}   90.4     1.116(0.447-2.784)[^b^](#tfn_002){ref-type="table-fn"}   95.6
  Oral squamous cell carcinoma   2                                       674/721        1.593(1.253-2.026)                                       3.9      1.674(1.292-2.169)                                       0        2.104(1.545-2.867)                                       33.0     1.420(1.102-1.829)                                       0        1.427(1.229-1.657)                                       6.9
  None small cell lung cancer    2                                       516/524        0.779(0.155-3.921)[^b^](#tfn_002){ref-type="table-fn"}   89.8     1.005(0.497-2.033)[^b^](#tfn_002){ref-type="table-fn"}   78.6     0.778(0.124-4.904)[^b^](#tfn_002){ref-type="table-fn"}   91.0     0.806(0.187-3.478)[^b^](#tfn_002){ref-type="table-fn"}   86.6     0.955(0.453-2.017)[^b^](#tfn_002){ref-type="table-fn"}   90.5
  Hepatocellular carcinoma       3                                       961/2530       1.503(0.907-2.492)[^b^](#tfn_002){ref-type="table-fn"}   82.4     1.699(0.873-3.307)[^b^](#tfn_002){ref-type="table-fn"}   92.2     2.022(0.861-4.746)[^b^](#tfn_002){ref-type="table-fn"}   91.8     1.179(0.962-1.445)                                       44.9     1.442(0.916-2.271)[^b^](#tfn_002){ref-type="table-fn"}   92.8
  Nasopharyngeal Carcinoma       3                                       2659/3088      1.200(0.883-1.631)[^b^](#tfn_002){ref-type="table-fn"}   73.7     1.146(0.918-1.431)[^b^](#tfn_002){ref-type="table-fn"}   65.4     1.339(1.040-1.724)b                                      52.0     1.257(1.092-1.447)                                       0        1.158(1.002-1.337)b                                      63.2
  Rental cell cancer             2                                       1356/1895      0.947(0.564-1.591)[^b^](#tfn_002){ref-type="table-fn"}   65.8     0.991(0.857-1.146)                                       1.9      0.948(0.764-1.176)                                       0        1.071(0.644-1.780)[^b^](#tfn_002){ref-type="table-fn"}   61.8     0.981(0.886-1.086)                                       0
   Other cancers                 6                                       1287/3179      1.174(0.851-1.619)[^b^](#tfn_002){ref-type="table-fn"}   61.5     0.952(0.704-1.286)[^b^](#tfn_002){ref-type="table-fn"}   73.1     1.105(0.705-1.733)[^b^](#tfn_002){ref-type="table-fn"}   75.0     1.218(1.003-1.480)                                       24.7     1.029(0.822-1.288)[^b^](#tfn_002){ref-type="table-fn"}   78.2

The bold values indicate that the association is significant

Number of comparisons

Random-effect model

![Forest plots of ORs with 95% CI for the *NFKB1* −94ins/del ATTG promoter polymorphism and risk of cancer in ethnicity (I *vs*. D)](oncotarget-07-58659-g003){#F3}

Publication bias {#s2_4}
----------------

The publication bias analysis was performed by Begg\'s funnel plot and Egger\'s test. The shape of the Begg\'s funnel plots seemed symmetrical (Figure [4](#F4){ref-type="fig"}) and Egger\'s test suggested no evidence of significant publication bias (*p* = 0.161 for the dominant model, *p* = 0.056 for the recessive model, *p* = 0.092 for the homozygote model, *p* = 0.239 for the heterozygote model, and *p* = 0.117 for the allele model) in this updated meta-analysis.

![Begg\'s funnel plot of the association between the NFKB1 −94ins/del ATTG promoter polymorphism and risk of cancer (II + ID *vs*. DD)](oncotarget-07-58659-g004){#F4}

Sensitivity analysis {#s2_5}
--------------------

The sensitivity analysis was performed by the sequential omission of individual studies. After excluding each study sequentially, we obtained statistically similar results (data not shown), suggesting that the data of our meta-analysis are relatively stable and credible. In addition, the random-effects model was compared with the fixed-effects model, and the statistically similar results were obtained in all genetic models.

DISCUSSION {#s3}
==========

In recent years, several investigators reported the association between the *NFKB1* −94ins/del ATTG promoter polymorphism and risk of cancers \[[@R14]--[@R35]\] such as bladder, ovarian, prostate, gastric and breast cancers as well as non-small cell lung, hepatocellular and nasopharyngeal carcinomas, but the results are inconclusive. Previous meta-analyses \[[@R45]--[@R48]\] had the drawback of a limited number of studies included and small sample sizes, or studies that were not in HWE were not excluded, which may affect the validity of the conclusions. Many relevant case-control studies were published recently \[[@R36]--[@R44]\], including more ethnicities and cancer types. However, the results of these articles were not consistent in previous meta-analyses. To provide a more comprehensive conclusion, we expanded the sample size to more than double through the addition of new studies that were published since the previous meta-analyses.

We performed a meta-analysis of 37 case-control studies from 33 articles (16,271 cases and 22,781 controls) to clarify the relationship between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer susceptibility. We found that the *NFKB1* −94ins/del ATTG promoter polymorphism was significantly associated with increased risk of cancer; this result was different than a previous meta-analysis \[[@R48]\], which reported that there was no association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer risk. The reasons for this difference could be explained as follows: 1) we included 37 case-control studies, *versus* only 11 studies (2,743 cases and 2,195 controls) in the previous meta-analysis, and therefore, the results of this meta-analysis were more credible; and 2) there may be some factors among the study populations that could influence the results, including age, gender, life style, and environment. In addition, when compared with the meta-analysis by Wenyuan Duan \[[@R45]\], although we reached the same conclusion in the terms of overall population, our analysis has some advantages: 1) we excluded articles that do not conform to HWE, whereas the previous meta-analyses did not; and 2) we included 37 studies, whereas previous meta-analyses included just 25 studies, which could lead to a lack of statistical power and reliability. However, we must be careful in explaining the results due to the moderate heterogeneity. To investigate the origin of the heterogeneity, we conducted a stratification analysis based on ethnicity and cancer type. In the subgroup analysis of ethnicity, we found a significant association of the *NFKB1* −94ins/del ATTG promoter polymorphism with increased and decreased cancer risk in Asian and Caucasian populations, respectively. Surprisingly, the results were different from the result shown by a previous meta-analysis \[[@R45]\], which conducted that the *NFKB1* −94ins/del ATTG promoter polymorphism was associated with risk in Asians but not in Caucasians population. The results may be explained by the following: 1) this discrepancy may be because of the limited sample size. The previous meta-analysis included only 9 articles (2047 cases and 2040 controls) in Caucasians, whereas we included 11 articles (3069 cases and 6584 controls); 2) we excluded the studies that do not follow HWE. Therefore, the results of this study are more reliable than the previous meta-analysis; 3) The sensitivity analysis was conducted through two methods in this meta-analysis, and the results were consistent with the previous results, suggesting the results of this study were stable.

Although the mechanism was not clear, we assumed that the mechanism underlying the cancer risk was related to the levels of p50. In recent studies \[[@R16],[@R68]\], it was shown that the probable mechanism of the observed association may be relative to the upregulation of the expression and activity of p50, once p50 is over expressed, it may influence cancer risk. However, cancer is a complex disease influenced by genetic and other non-genetic factors such as environment, lifestyle and habits that might influence the incidence ratio of cancer\[[@R64]--[@R66]\]. The *NFKB1* −94ins/del ATTG promoter polymorphism was just one of susceptibility genes, and all these non-genetic factors could influence the expression of the gene. Therefore, the differences in this *NFKB1* polymorphism in Asians and Caucasians may result from different genetic background, environment, lifestyle or other factors.

According to the results of the analysis of the relationship between the *NFKB1* −94ins/del ATTG promoter polymorphism and subtypes of cancer, the *NFKB1* −94ins/del ATTG promoter polymorphism is a risk factor for oral squamous cell carcinoma, ovarian cancer and nasopharyngeal carcinoma. This result suggests that the *NFKB1* gene might have some relevance in these cancers. The inconsistent may be caused by their different micro-environment, because the same genetic factor might have different correlations in different cancer site \[[@R67]\]. Our study has a relatively small number of cases in each cancer type, which might create significant or insignificant associations by chance due to insufficient statistical power. Therefore, further research should enlarge the sample for each cancer type and validate the cancer-specificity effect of this functional polymorphism on cancer susceptibility.

This study has several limitations, like any meta-analysis. First, moderate heterogeneity was detected in some comparisons and may distort the meta-analysis. Second, the non-genetic risk factors such as environment are also important in the incidence ratio of cancer. Unfortunately, there were not enough data for further subgroup analysis; therefore, the results of subgroup analysis may affect the validity of the conclusions. Third, in the subgroup analysis, we found that our analysis was limited to Asian and Caucasian populations, so we do not know whether these conclusions can also be adopted in other populations. This may cause publication bias. Finally, the sample sizes for each type of cancer were relatively small, so further research should enlarge the sample sizes to obtain more accurate conclusions.

Despite these limitations, our study has several strengths. First, all of the studies that we chose agreed with HWE, which may increase the validity of the conclusions. Second, the sample size of our study was more than double that of the previous meta-analysis, significantly increasing the statistical power. Although this updated meta-analysis had the above-mentioned shortcomings, we tried to control them through perfected searching, sifting the good ones from the bad and performing the statistical analyses strictly.

CONCLUSIONS {#s4}
===========

We conclude that the *NFKB1* −94ins/del ATTG promoter polymorphism is associated with cancer risk not only in Asian populations, but also in Caucasian populations. Moreover, there might be a significant association with increased susceptibility between the *NFKB1* −94ins/del ATTG promoter polymorphism and ovarian cancer, oral squamous cell carcinoma, and nasopharyngeal carcinoma. Well-designed studies with larger representative sample sizes are necessary to confirm our results.

MATERIALS AND METHODS {#s5}
=====================

The systematic review and meta-analysis was in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines

Publication search {#s5_1}
------------------

A systematic search of the PubMed, Web of Science, Science Direct, Ovid, China National Knowledge Infrastructure (CNKI) and Wan fang Data electronic databases was performed with the following key words: ("polymorphisms" OR "polymorphism" OR "SNP" OR "single nucleotide polymorphism" OR "variant" OR "mutation") AND ("neoplasm" OR "cancer" OR "tumor" OR "carcinoma" OR "carcinogenesis") AND ("NF-κB1" OR "Nuclear factor-κB1" OR "Nuclear factor κB1" OR "NFKB1" OR "nuclear factor kappa B1" OR "NF kappa B1" OR "nuclear factor kB1" OR "rs28362491").

Inclusion criteria {#s5_2}
------------------

No language or other restrictions were imposed in this study and the inclusion criteria were as follows: 1) case-control design; 2) studies evaluating the association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer risk; 3) studies describing the genotype distributions in detail to calculate the OR and 95%CI in cases and controls; and 4) the distribution data in controls must be consistent with Hardy-Weinberg Equilibrium (HWE).

Exclusion criteria {#s5_3}
------------------

The exclusion criteria in this meta-analysis were as follows: 1) not concerned with cancer risk; 2) only a case population; 3) duplication of a previous publication; 4) the control group does not conform to HWE; and 5) animal studies.

Data extraction {#s5_4}
---------------

According to the criteria listed above, information was carefully extracted from eligible studies independently by each investigator (Y.Q.L. and D.W.). The following information was collected from each study: surname of the first author, year of publication, ethnicity of subjects, genotyping method, frequencies of the genotypes in cases and controls, cancer type. The different ethnicities were categorized as Caucasian or Asian. Studies that investigated more than one type of cancer were regarded as individual datasets only in subgroup analyses according to cancer type. Any discrepancy was resolved through discussion.

Statistical analysis {#s5_5}
--------------------

The strength of association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer was estimated through OR with 95% CI. The combined ORs were determined by the Z test, and a *P* value of \<0.05 was considered to be statistically significant. The *NFKB1* −94ins/del ATTG promoter polymorphism consists of three genotypes: homozygote insertion or wild-type (II), homozygote deletion or variant (DD), and heterozygous ins/del (ID). We measured the association based on five different genetic models: the dominant (II+ID *vs*. DD), recessive (II *vs*. ID + DD), homozygote (II *vs*. DD), heterozygote (ID *vs*. DD), and allele (I *vs*. D) models. To investigate the origin of heterogeneity, subgroup analyses based on ethnicity (Caucasian and Asian) and cancer type were performed to identify the association between the *NFKB1* −94ins/del ATTG promoter polymorphism and cancer susceptibility.

We used the *Q* and *I^2^* statistical tests to check the statistical heterogeneity among studies. If the *P* value was \< 0.05 and *I^2^* ≥ 50% indicating heterogeneity, then a random-effect model was chosen to calculate the pooled OR; otherwise, a fixed-effect model was selected \[[@R12]\]. A sensitivity analysis was conducted by sequentially excluding each study to evaluate the stability of the results. The publication bias was estimated by Egger\'s test and Begg\'s funnel plots, with potential publication bias if *p*\<0.05 and the plot was asymmetrical \[[@R13]\]. The statistical analyses were performed using STATA 11.0 software (Stata Corp, College Station, TX, USA).
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